Tim Mayleben, Esperion CEO

Es­pe­ri­on's strug­gling-to-mar­ket, would-be block­buster finds fresh in­fu­sion of cash

A year af­ter win­ning ap­proval for their heart dis­ease pill, Es­pe­ri­on is still strug­gling to sell it.

Burned by a mid-pan­dem­ic launch, the Ann Ar­bor, MI-based biotech pock­et­ed just $12.1 mil­lion last year on a drug they be­lieved would one day be a block­buster. An­a­lysts ex­pect a boost in Q1 but not a sig­nif­i­cant one — $11 to $12 mil­lion — and not enough to make their long-term bal­ance sheet look par­tic­u­lar­ly more at­trac­tive.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.